Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Will Alkermes Data Package Support ALKS 5461 Approval?

Watch gears up close

Related Content

Do Negative Trials Count More Than Successful Ones?

Dec 01 2015

FDA's Thinking On New Psychiatric Endpoints: What Does Brintellix CRL Portend For Nuplazid?

Apr 04 2016

Keeping Track: Rexulti, Iressa Approved; Takeda Submits Oral Myeloma Drug Ixazomib

Jul 20 2015

Alkermes Strategy After Antidepressant Failures Doubted By Wall Street

Jan 21 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

FDA Reverses Position On Fabre-Kramer's Gepirone, Clearing Way For Approval

Mar 18 2016

An Iffy Future For Alkermes After Failed Trials

Jan 22 2016

COMMENT: Alkermes Needs New Strategy In Wake Of Trial Failures

Jan 26 2016

Keeping Track: Approvals For Nuplazid, Cabometyx, Bevespi And More; Digital Aripiprazole Tablet Needs More Study

May 02 2016

Related Companies

Alkermes plc

Acadia Pharmaceuticals Inc.

Harvard University

Otsuka Holdings Co., Ltd.

H. Lundbeck A/S

Fabre-Kramer Pharmaceuticals

Sarepta Therapeutics, Inc.

Additional Topics

Research & Development Review Pathway Regulation Drug Review Neurology BioPharmaceutical

More from R&D

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window